Autoinflammatory diseases

Best Practice and Research: Clinical Rheumatology

Volumn 22, Issue 5, 2008, Pages 811-829

  Touitou, Isabelle ^a   Koné Paut, Isabelle ^b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

autoinflammatory; Beh et; FMF; IL 1 blockade; recurrent fevers

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CASPASE INHIBITOR; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CELL PROTEIN; COLCHICINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; ETANERCEPT; HLA B51 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MEVALONATE KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; THALIDOMIDE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1;

ABDOMINAL PAIN; APOPTOSIS; ARTHRITIS; AUTOINFLAMMATORY DISEASE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; BEHCET DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CRYOPYRIN ASSOCIATED PERIODIC SYNDROME; CYTOKINE RELEASE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG MEGADOSE; FAMILIAL MEDITERRANEAN FEVER; FEVER; GENETIC IDENTIFICATION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; MEVALONATE KINASE DEFICIENCY; MONOGENIC DISORDER; MONOTHERAPY; NEUROTOXICITY; PAPA SYNDROME; PATHOPHYSIOLOGY; PFAPA SYNDROME; PRIORITY JOURNAL; REVIEW; SCHNITZLER SYNDROME; SIGNAL TRANSDUCTION; SKIN DISEASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UNSPECIFIED SIDE EFFECT; UVEITIS;

AUTOIMMUNE DISEASES; CARRIER PROTEINS; FAMILIAL MEDITERRANEAN FEVER; HUMANS; INFLAMMATION; MEVALONATE KINASE DEFICIENCY; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 56349142987     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2008.08.009     Document Type: Review

References (89)

1. McDermott M.F., and Aksentijevich I. The autoinflammatory syndromes. Current Opinion in Allergy and Clinical Immunology 2 6 (2002) 511-516
2. Hull K.M., Shoham N., Chae J.J., et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Current Opinion in Rheumatology 15 1 (2003) 61-69
3. Brydges S., and Kastner D.L. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Current Topics in Microbiology and Immunology 305 (2006) 127-160
4. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of Leukocyte Biology 81 1 (2007) 1-5
5. Creagh E.M., and O'Neill L.A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends in Immunology 27 8 (2006) 352-357
6. Leber J.H., Crimmins G.T., Raghavan S., et al. Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen. PLoS pathogens 4 1 (2008) e6
7. McDermott M.F. A common pathway in periodic fever syndromes. Trends in Immunology 25 9 (2004) 457-460
8. Hoffman H.M., Mueller J.L., Broide D.H., et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nature Genetics 29 3 (2001) 301-305
9. Feldmann J., Prieur A.M., Quartier P., et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. American Journal of Human Genetics 71 1 (2002) 198-203
10. Martinon F., Burns K., and Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Molecular Cell 10 2 (2002) 417-426
11. Agostini L., Martinon F., Burns K., et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20 3 (2004) 319-325
12. The French FMF Consortium. A candidate gene for familial Mediterranean fever. Nature Genetics 17 1 (1997) 25-31
13. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90 4 (1997) 797-807
14. Chae J.J., Wood G., Masters S.L., et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proceedings of the National Academy of Sciences of the United States of America 103 26 (2006) 9982-9987
15. Dowds T.A., Masumoto J., Chen F.F., et al. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochemical and Biophysical Research Communications 302 3 (2003) 575-580
16. Papin S., Cuenin S., Agostini L., et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ (2007)
17. Shoham N.G., Centola M., Mansfield E., et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proceedings of the National Academy of Sciences of the United States of America 100 23 (2003) 13501-13506
18. Jeru I., Duquesnoy P., Fernandes-Alnemri T., et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proceedings of the National Academy of Sciences of the United States of America 105 5 (2008) 1614-1619
19. Drenth J.P., Cuisset L., Grateau G., et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nature Genetics 22 2 (1999) 178-181
20. Houten S.M., Kuis W., Duran M., et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nature Genetics 22 2 (1999) 175-177
21. Houten S.M., Frenkel J., and Waterham H.R. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cellular and Molecular Life Sciences 60 6 (2003) 1118-1134
22. Mandey S.H., Kuijk L.M., Frenkel J., and Waterham H.R. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis and Rheumatism 54 11 (2006) 3690-3695
23. Hoffmann G.F., Wiesmann U.N., Brendel S., et al. Regulatory adaptation of isoprenoid biosynthesis and the LDL receptor pathway in fibroblasts from patients with mevalonate kinase deficiency. Pediatric Research 41 4 Pt 1 (1997) 541-546
24. McDermott M.F., Aksentijevich I., Galon J., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97 1 (1999) 133-144
25. Miceli-Richard C., Lesage S., Rybojad M., et al. CARD15 mutations in Blau syndrome. Nature Genetics 29 1 (2001) 19-20
26. Pullen S.S., Labadia M.E., Ingraham R.H., et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 38 31 (1999) 10168-10177
27. Ogura H., Tsukumo Y., Sugimoto H., et al. Ectodomain shedding of TNF receptor 1 induced by protein synthesis inhibitors regulates TNF-alpha-mediated activation of NF-kappaB and caspase-8. Experimental Cell Research 314 6 (2008) 1406-1414
28. Aksentijevich I., Galon J., Soares M., et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. American Journal of Human Genetics 69 2 (2001) 301-314
29. Simon A., and van der Meer J.W. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 292 1 (2007) R86-R98
30. Stojanov S., and McDermott M.F. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Reviews in Molecular Medicine 7 22 (2005) 1-18
31. Gul A. Behcet's disease as an autoinflammatory disorder. Current Drug Targets. Inflammation and Allergy 4 1 (2005) 81-83
32. Gul A. Behcet's disease: an update on the pathogenesis. Clinical and Experimental Rheumatology 19 5 Suppl. 24 (2001) S6-S12
33. Abdel-Aziz A.H., and Fairburn E.A. Familial Behcet's syndrome. Cutis 21 5 (1978) 649-652
34. Kera J., Mizuki N., Ota M., et al. Significant associations of HLA-B*5101 and B*5108, and lack of association of class II alleles with Behcet's disease in Italian patients. Tissue Antigens 54 6 (1999) 565-571
35. Mizuki N., Ota M., Kimura M., et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behcet disease. Proceedings of the National Academy of Sciences of the United States of America 94 4 (1997) 1298-1303
36. Molinari N., Kone Paut I., Manna R., et al. Identification of an autosomal recessive mode of inheritance in paediatric Behcet's families by segregation analysis. American Journal of Medical Genetics. Part A 122 2 (2003) 115-118
37. de Benedetti F., and Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?. Arthritis and Rheumatism 52 3 (2005) 687-693
38. Pascual V., Allantaz F., Arce E., et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. The Journal of Experimental Medicine 201 9 (2005) 1479-1486
39. Grateau G., Jeru I., Rouaghe S., et al. Amyloidosis and autoinflammatory syndromes. Current Drug Targets. Inflammation and Allergy 4 1 (2005) 57-65
40. Aksentijevich I., Putnam C.D., Remmers E.F., et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis and Rheumatism 56 4 (2007) 1273-1285
41. Heller H., Sohar E., and Pras M. Ethnic distribution and amyloidosis in familial Mediterranean fever (FMF). Pathologia Et Microbiologia 24 (1961) 718-723
42. Livneh A., Langevitz P., Zemer D., et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis and Rheumatism 40 10 (1997) 1879-1885
43. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. European Journal of Human Genetics 9 7 (2001) 473-483
44. Touitou I., Sarkisian T., Medlej-Hashim M., et al. Country as the primary risk factor for renal amyloidosis in familial mediterranean fever. Arthritis and Rheumatism 56 5 (2007) 1706-1712
45. Zemer D., Pras M., Sohar E., et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. The New England Journal of Medicine 314 16 (1986) 1001-1005
46. Tunca M., Akar S., Soyturk M., et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clinical and Experimental Rheumatology 22 4 Suppl. 34 (2004) S37-S40
47. Sayarlioglu H., Erkoc R., Sayarlioglu M., et al. Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatology International (2006)
48. Seyahi E., Ozdogan H., Masatlioglu S., and Yazici H. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clinical and Experimental Rheumatology 20 4 Suppl. 26 (2002) S43-S44
49. Tallon B., and Corkill M. Peculiarities of PAPA syndrome. Rheumatology (Oxford, England) 45 9 (2006) 1140-1143
50. Stichweh D.S., Punaro M., and Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatric Dermatology 22 3 (2005) 262-265
51. Houten S.M., Frenkel J., Kuis W., et al. Molecular basis of classical mevalonic aciduria and the hyperimmunoglobulinaemia D and periodic fever syndrome: high frequency of 3 mutations in the mevalonate kinase gene. Journal of Inherited Metabolic Disease 23 4 (2000) 367-370
52. Haas D., and Hoffmann G.F. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet Journal of Rare Diseases 1 (2006) 13
53. Houten S.M., Wanders R.J., and Waterham H.R. Biochemical and genetic aspects of mevalonate kinase and its deficiency. Biochimica Et Biophysica Acta 1529 1-3 (2000) 19-32
54. Hoffmann G.F., Brendel S.U., Scharfschwerdt S.R., et al. Mevalonate kinase assay using DEAE-cellulose column chromatography for first-trimester prenatal diagnosis and complementation analysis in mevalonic aciduria. Journal of Inherited Metabolic Disease 15 5 (1992) 738-746
55. Ammouri W., Cuisset L., Rouaghe S., et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology (Oxford, England) 46 10 (2007) 1597-1600
56. Lachmann H.J., Goodman H.J., Andrews P.A., et al. AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases. Arthritis and Rheumatism 54 6 (2006) 2010-2014
57. Simon A., Drewe E., van der Meer J.W., et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clinical Pharmacology and Therapeutics 75 5 (2004) 476-483
58. Bodar E.J., van der Hilst J.C., Drenth J.P., et al. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. The Netherlands Journal of Medicine 63 7 (2005) 260-264
59. Drenth J.P., Vonk A.G., Simon A., et al. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. The Journal of Pharmacology and Experimental Therapeutics 298 3 (2001) 1221-1226
60. Williamson L.M., Hull D., Mehta R., et al. Familial Hibernian fever. The Quarterly Journal of Medicine 51 204 (1982) 469-480
61. Ravet N., Rouaghe S., Dode C., et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Annals of the Rheumatic Diseases 65 9 (2006) 1158-1162
62. Drewe E., McDermott E.M., Powell P.T., et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford, England) 42 2 (2003) 235-239
63. Gattorno M., Pelagatti M.A., Meini A., et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis and Rheumatism 58 5 (2008) 1516-1520
64. Marshall G.S., Edwards K.M., and Lawton A.R. PFAPA syndrome. The Pediatric Infectious Disease Journal 8 9 (1989) 658-659
65. Wong K.K., Finlay J.C., and Moxham J.P. Role of Tonsillectomy in PFAPA Syndrome. Archives of Otolaryngology Head & Neck Surgery 134 1 (2008) 16-19
66. Eiling E., Schroder J.O., Gross W.L., et al. The Schnitzler syndrome: Chronic urticaria and monoclonal gammopathy - an autoinflammatory syndrome?. Journal der Deutschen Dermatologischen Gesellschaft (2008)
67. Wastiaux H., Barbarot S., Gagey-Caron V., et al. Schnitzler syndrome: a dramatic improvement with anakinra. Journal of the European Academy of Dermatology and Venereology (2008)
68. Miyachi Y., Taniguchi S., Ozaki M., and Horio T. Colchicine in the treatment of the cutaneous manifestations of Behcet's disease. The British Journal of Dermatology 104 1 (1981) 67-69
69. Hamuryudan V., Mat C., Saip S., et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 128 6 (1998) 443-450
70. Tsambaos D., Eichelberg D., and Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha- interferon. Archives for Dermatological Research 278 4 (1986) 335-336
71. Sakane T., Takeno M., Suzuki N., and Inaba G. Behcet's disease. The New England Journal of Medicine 341 17 (1999) 1284-1291
72. Kotter I., Vonthein R., Zierhut M., et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Seminars in Arthritis and Rheumatism 33 5 (2004) 311-319
73. Guillaume-Czitrom S., Berger C., Pajot C., et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford, England) 46 10 (2007) 1570-1573
74. Melikoglu M., Fresko I., Mat C., et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. The Journal of Rheumatology 32 1 (2005) 98-105
75. Milhavet F., Cuisset L., Hoffman H.M., et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Human Mutation 29 6 (2008) 803-808
76. Touitou I., Magne X., Molinari N., et al. MEFV mutations in Behcet's disease. Human Mutation 16 3 (2000) 271-272
77. Atagunduz P., Ergun T., and Direskeneli H. MEFV mutations are increased in Behcet's disease (BD) and are associated with vascular involvement. Clinical and Experimental Rheumatology 21 4 Suppl. 30 (2003) S35-S37
78. Amoura Z., Dode C., Hue S., et al. Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease. Arthritis and Rheumatism 52 2 (2005) 608-611
79. Kone-Paut I., Sanchez E., Le Quellec A., et al. Autoinflammatory gene mutations in Behcet's disease. Annals of the Rheumatic Diseases (2007)
80. Drewe E., Huggins M.L., Morgan A.G., et al. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford, England) 43 11 (2004) 1405-1408
81. Takada K., Aksentijevich I., Mahadevan V., et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis and Rheumatism 48 9 (2003) 2645-2651
82. Cortis E., De Benedetti F., Insalaco A., et al. Abnormal production of tumor necrosis factor (TNF) - alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome. [corrected]. The Journal of Pediatrics 145 6 (2004) 851-855
83. Sfikakis P.P., Theodossiadis P.G., Katsiari C.G., et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358 9278 (2001) 295-296
84. Lovell D.J., Giannini E.H., Reiff A., et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis and Rheumatism 48 1 (2003) 218-226
85. Hawkins P.N., Lachmann H.J., Aganna E., and McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis and Rheumatism 50 2 (2004) 607-612
86. Calligaris L., Marchetti F., Tommasini A., and Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. European Journal of Pediatrics 167 6 (2008) 695-696
87. Milledge J., Shaw P.J., Mansour A., et al. Allogenic bone marrow transplantation: cure for familial Mediterranean fever. Blood 100 3 (2002) 774-777
88. Touitou I. Should patients with FMF undergo BMT?. Blood 101 3 (2003) 1205 author reply -6
89. Neven B., Valayannopoulos V., Quartier P., et al. Allogeneic bone marrow transplantation in mevalonic aciduria. The New England Journal of Medicine 356 26 (2007) 2700-2703